Vanguard Group Inc. Has $7.31 Billion Position in Cencora, Inc. $COR

Vanguard Group Inc. grew its stake in Cencora, Inc. (NYSE:COR) by 4.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,395,547 shares of the company’s stock after acquiring an additional 916,506 shares during the period. Vanguard Group Inc. owned 0.12% of Cencora worth $7,311,810,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Harbour Investments Inc. boosted its stake in shares of Cencora by 108.2% in the 2nd quarter. Harbour Investments Inc. now owns 1,951 shares of the company’s stock valued at $585,000 after purchasing an additional 1,014 shares during the last quarter. Private Trust Co. NA lifted its stake in shares of Cencora by 3.3% in the 2nd quarter. Private Trust Co. NA now owns 1,996 shares of the company’s stock valued at $599,000 after purchasing an additional 63 shares during the period. Stratos Wealth Partners LTD. grew its stake in shares of Cencora by 31.6% during the second quarter. Stratos Wealth Partners LTD. now owns 1,028 shares of the company’s stock worth $308,000 after purchasing an additional 247 shares during the period. William Blair Investment Management LLC increased its holdings in Cencora by 4,778.9% in the second quarter. William Blair Investment Management LLC now owns 37,665 shares of the company’s stock valued at $11,294,000 after purchasing an additional 36,893 shares during the last quarter. Finally, United Bank lifted its stake in Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after buying an additional 305 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Up 2.7%

Shares of COR stock opened at $360.59 on Tuesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm’s 50-day moving average is $347.97 and its 200-day moving average is $329.40. The stock has a market cap of $70.15 billion, a price-to-earnings ratio of 43.34, a PEG ratio of 1.66 and a beta of 0.68. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.73 EPS. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is currently 28.85%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Barclays increased their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by company insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.